Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Respiratory Syncytial Virus (RSV) F protein is a type I integral membrane fusion glycoprotein essential for viral entry into host cells. Site II is one of several well-characterized antigenic regions on both preF and postF forms. Antibodies targeting site II can neutralize RSV by blocking its ability to fuse with host membranes.
Neutralizing antibody that blocks viral fusion
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Respiratory Syncytial Virus Fusion (F) protein Site II (RSV F protein Site II).